Compare HSBC Holdings plc (HSBC) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Revvity Inc — how do they compare? HSBC Holdings plc trades at $93.03 (market cap $311.92B), while Revvity Inc trades at $154.34 (market cap $16.98B). The key difference: HSBC Holdings plc is far larger — about 18.4× Revvity Inc's market cap, and HSBC Holdings plc pays the higher dividend (4.05%). Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and Revvity Inc for 12 Days on average.
| HSBC | RVTY | |
|---|---|---|
Market Cap | $311.92B | $16.98B |
Volume | 3,546,658 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $107.86 | $157.36 |
52-Week Low | $65.67 | $82.26 |
Typical Hold Time | 36 Days | 12 Days |
Enterprise Value | $222.19B | $19.30B |
Dividend Yield | 4.05% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.96, down 0.8% with bearish technical indicators. The bank shows strong profitability with 34.54% net margin and 12.44% ROE, while trading at reasonable valuations (P/E 13.23). Recent earnings show mixed results with Q2 beat but Q1 miss. Analyst sentiment is mixed with 38.1% buy ratings amid strategic expansions in US wealth management and Asian markets.
HSBC presents a balanced opportunity with solid fundamentals offset by near-term technical weakness. Growth initiatives in wealth management and Asian markets provide upside potential, while CFO transition and European restructuring pose execution risks. The stock's valuation remains attractive relative to earnings power.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
